As of close of business last night, Unity Biotechnology Inc’s stock clocked out at $1.70, down -7.10% from its previous closing price of $1.83. In other words, the price has decreased by -$0.1300 from its previous closing price. On the day, 655982 shares were traded.
Ratios:
To gain a deeper understanding of UBX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.74 and its Current Ratio is at 5.74. In the meantime, Its Debt-to-Equity ratio is 0.67 whereas as Long-Term Debt/Eq ratio is at 0.67.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on November 16, 2023, Upgraded its rating to Outperform and sets its target price to $4 from $2 previously.
Mizuho Upgraded its Neutral to Buy on November 10, 2021, whereas the target price for the stock was revised from $5 to $7.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 02 when Ghosh Anirvan sold 680 shares for $1.71 per share. The transaction valued at 1,163 led to the insider holds 78,746 shares of the business.
Ghosh Anirvan sold 1,183 shares of UBX for $2,023 on Jan 30. The Chief Executive Officer now owns 79,426 shares after completing the transaction at $1.71 per share. On Nov 02, another insider, Ghosh Anirvan, who serves as the Chief Executive Officer of the company, sold 589 shares for $1.83 each. As a result, the insider received 1,078 and left with 80,609 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, UBX now has a Market Capitalization of 28.53M and an Enterprise Value of 7.03M. Its current Enterprise Value per Revenue stands at 29.79 whereas that against EBITDA is -0.15.
Stock Price History:
Over the past 52 weeks, UBX has reached a high of $5.11, while it has fallen to a 52-week low of $1.46. The 50-Day Moving Average of the stock is 1.7947, while the 200-Day Moving Average is calculated to be 2.3085.
Shares Statistics:
It appears that UBX traded 90.72K shares on average per day over the past three months and 79.53k shares per day over the past ten days. A total of 16.79M shares are outstanding, with a floating share count of 15.36M. Insiders hold about 8.51% of the company’s shares, while institutions hold 18.69% stake in the company. Shares short for UBX as of Feb 15, 2024 were 320.03k with a Short Ratio of 3.53, compared to 307.1k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.91% and a Short% of Float of 1.93%.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.72 for the current quarter, with a high estimate of -$0.39 and a low estimate of -$1.15, while EPS last year was -$1. The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.38 and low estimates of -$0.65.
Analysts are recommending an EPS of between -$2.9 and -$3.81 for the fiscal current year, implying an average EPS of -$3.25. EPS for the following year is -$2.71, with 3 analysts recommending between -$1.5 and -$3.83.
